Research

OpenAI and Novo Nordisk Partnership: What Was and Was Not Disclosed

Novo Nordisk and OpenAI announced a partnership on April 14, 2026 covering drug discovery through commercial operations, with full integration targeted by end of 2026. No financial terms were given. Status as of November 13, 2026.

By Ramanath, CTO & Co-Founder at Presenc AI · Last updated: November 2026

Novo Nordisk and OpenAI announced a strategic partnership on April 14, 2026. It covers the use of OpenAI's models from drug discovery through manufacturing, supply chain and commercial operations, starting with pilot programmes, with full integration expected by the end of 2026. The companies gave no financial terms, no contract length and no model names. In September 2026 Novo Nordisk added a separate agreement with Anthropic. As of November 13, 2026, we found no company update on whether the integration target has been met.

Key Dates

DateEvent
April 14, 2026Novo Nordisk and OpenAI announce the partnership from Bagsværd, Denmark
April 16, 2026OpenAI introduces GPT-Rosalind, a life-sciences model. Press coverage lists Novo Nordisk among the organisations working with it
September 11, 2026OpenAI says GPT-Rosalind is leaving research preview
September 16, 2026Novo Nordisk announces a collaboration with Anthropic. Euronews reports the company is already using GPT-Rosalind
End of 2026Target for full integration of OpenAI's technology, as stated in April

What Was Disclosed and What Was Not

ItemStatusDetail
ScopeDisclosedAnalysing complex datasets, identifying drug candidates, and shortening the time from research to patients. Also manufacturing, supply chain, distribution and corporate operations
RolloutDisclosedPilots in research and development, manufacturing and commercial operations. Full integration by the end of 2026
TrainingDisclosedOpenAI will help raise AI skills across Novo Nordisk's global workforce
GovernanceDisclosed in general termsThe release refers to strict data protection, governance and human oversight
Financial termsNot disclosed
Contract lengthNot disclosed
Models usedNot named in the releaseLater coverage says the company uses GPT-Rosalind
ExclusivityNot statedThe release says the deal builds on existing AI work with other technology partners
Specific drug programmesNot disclosed
What data OpenAI can accessNot disclosed

This is a technology agreement. No molecule is licensed and there are no milestone payments, which sets it apart from most entries in the AI pharma deal tracker.

What the Executives Said

In the release, Novo Nordisk chief executive Mike Doustdar said AI lets the company analyse datasets at a scale that was "previously impossible". OpenAI chief executive Sam Altman said AI in life sciences "can help people live better, longer lives".

The Anthropic Agreement

On September 16, 2026, Novo Nordisk said it would also use Anthropic's Claude models in R&D and test Claude Science, according to Euronews. Terms were not disclosed. The report presents it as part of a wider investment in AI and does not say whether the two agreements overlap. More on the Anthropic life sciences partnerships page.

OpenAI's Other Life-Science Work

ItemDateWhat it is
GPT-RosalindApril 16, 2026A reasoning model for biology, drug discovery and translational medicine. First offered as a research preview to qualified enterprise customers in the United States through a trusted-access programme
Life sciences plugin for CodexApril 2026A free plugin connecting to more than 50 public databases and tools, including AlphaFold and BindingDB
GPT-Rosalind leaves previewSeptember 11, 2026Available to eligible organisations worldwide, still through trusted access. Third-party trackers list API pricing of $5 per million input tokens and $25 per million output tokens from October 5, 2026
Named GPT-Rosalind organisationsApril 2026Amgen, Moderna, Thermo Fisher Scientific, Novo Nordisk, the Allen Institute and the UCSF School of Pharmacy, among others, per launch coverage
Thermo Fisher ScientificOctober 2025A collaboration on drug development, per R&D World
Retro Biosciences2025A small protein-engineering model, GPT-4b micro, built with Retro
Eli LillyJune 2024A collaboration on antimicrobials for drug-resistant bacteria, per BioSpace

OpenAI has not announced drug programmes of its own. How GPT-Rosalind compares with the other frontier-lab efforts is at Claude Science vs GPT-Rosalind vs Isomorphic Labs.

Methodology

Partnership facts come from the Novo Nordisk company release of April 14, 2026, read on Inderes. GPT-Rosalind details come from The Decoder and eWeek, because OpenAI's own announcement page blocked our reader. The September update and pricing come from AI Catchup, a secondary source. The Anthropic agreement is from Euronews. Status as of November 13, 2026.

Frequently Asked Questions

April 14, 2026, in a Novo Nordisk company release from Bagsværd, Denmark.
The companies did not disclose financial terms or the length of the agreement.
According to the April 14, 2026 release: analysing complex datasets, identifying promising drug candidates, shortening the time from research to patients, and improving efficiency in manufacturing, supply chain, distribution and corporate operations. Pilots come first, with full integration expected by the end of 2026.
Nothing published says so. The April release notes existing AI work with other technology partners, and on September 16, 2026 the company announced a separate collaboration with Anthropic.
Launch coverage of GPT-Rosalind in April 2026 listed Novo Nordisk among the organisations working with the model, and Euronews reported in September 2026 that the company was already using it. The April partnership release itself does not name a model.

Hire agents, not agencies.

Presenc is a team of AI agents that builds the pages your buyers search for, and a person checks every one. We take on a few teams at a time.

Request access